ALBO News and Press, Albireo Pharma Inc. From 11/17/20

The following slide deck was published by Albireo Pharma, Inc. in conjunction with this event. For further details see: Albireo Pharma (ALBO) Investor Presentation - Slideshow

Albireo Pharma (ALBO) announces new data in progressive familial intrahepatic cholestasis ((PFIC)) confirming statistically significant reductions in serum bile acids (sBAs) and improvements in pruritus for odevixibat, a potent, once-daily, non-systemic ileal bile acid transport inhibitor (IB...

- PEDFIC 1 meets both U . S . and EU primary and secondary endpoints with high ly statistically significant reductions in serum bile acids and pruritus - - Interim results from long-term exte...

BOSTON, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer, will present via webcast at the 2020 Jefferies London Hea...

Albireo Pharma (ALBO): Q3 GAAP EPS of -$1.96 misses by $0.45.Revenue of $2.13M (+53.2% Y/Y) beats by $0.5M.Press Release For further details see: Albireo Pharma EPS misses by $0.45, beats on revenue

- P ositive P hase 3 d ata for o devixibat in PFIC with filings on track for no later than early 202 1 - - Phase 3 PFIC data accepted as late breakers at upcoming AASLD Meeting - - Introd...

- Final PEDFIC 1 and interim PEDFIC 2 results accepted at AASLD’s The Liver Meeting 2020 - - PEDFIC 1 and PEDFIC 2 : largest global Phase 3 in children with PFIC types 1, 2 & 3 - - T...

- Research continues to show potential of odevixibat as first drug therapy for PFIC and in other rare liver diseases- - Scientific leadership demonstrate s c ompany’s commitment to increase understanding of rare pedi...

Tracking insider purchases is an overlooked but very informative strategy. It can provide undervalued stocks in the market and can make assumptions for future market returns. September's number of insider purchases was close to the historical average, indicating that insiders are not ...

BOSTON, Oct. 05, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, joins the PFIC Advocacy and Resource Network (PFIC Network) in recognition of PFIC Awareness Day 2020, a global effor...